Related Experiment Videos
Dose response and atypical antipsychotics in schizophrenia
Bruce J Kinon1, Jonna Ahl, Virginia L Stauffer
1Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA.
CNS Drugs
|June 30, 2004
Summary
Atypical antipsychotics offer improved schizophrenia symptom relief but have dose limitations. Optimal dosing varies, with some drugs showing efficacy increases at higher doses without significant adverse events, while others do not.
Area of Science:
- Psychiatry
- Pharmacology
- Clinical Medicine
Background:
- Conventional antipsychotics for schizophrenia exhibit dose-related efficacy and adverse effects, limiting their use.
- Atypical antipsychotics offer broader symptom relief but also possess dose limitations.
- Understanding dose-response relationships is crucial for optimizing treatment.
Purpose of the Study:
- To review the dose-response relationships of atypical antipsychotics in schizophrenia treatment.
- To analyze data from pivotal, randomized clinical trials.
- To identify optimal and potentially limiting dosages for atypical antipsychotics.
Main Methods:
- Systematic review of randomized controlled trials (RCTs) for atypical antipsychotics.
- Analysis of dose-response data for efficacy and adverse events.
- Focus on pivotal trials for clozapine, risperidone, olanzapine, ziprasidone, quetiapine, and aripiprazole.
Main Results:
- Clozapine shows dose-related efficacy up to 600 mg/day for treatment-resistant schizophrenia, with increased seizure risk at higher doses.
- Risperidone's efficacy is compromised by dose-related adverse events.
- Olanzapine efficacy appears dose-related within 10-20 mg/day, with potential for improved efficacy at higher doses without significantly increased adverse events. Data for ziprasidone, quetiapine, and aripiprazole are less established.
Conclusions:
- Atypical antipsychotics have complex dose-response profiles requiring careful consideration.
- Optimal dosing strategies vary among agents, impacting efficacy and tolerability.
- Further research is needed to fully elucidate the dose-response relationships of atypical antipsychotics for schizophrenia.